Name | (E)-3-[1-(benzenesulfonyl)-2,3-dihydroindol-5-yl]-N-hydroxyprop-2-enamide |
---|---|
Synonyms |
3-(1-(Benzenesulfonyl)-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide
2-Propenamide,3-(2,3-dihydro-1-(phenylsulfonyl)-1H-indol-5-yl)-N-hydroxy UNII-T65L58FI65 |
Description | MPT0E028 is an orally active and selective HDAC inhibitor with IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively[1]. MPT0E028 reduces the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma. MPT0E028 has good anticancer activity[2]. |
---|---|
Related Catalog | |
Target |
HDAC1:53.0 nM (IC50) HDAC2:106.2 nM (IC50) HDAC6:29.5 nM (IC50) HDAC8:2532.6 nM (IC50) Akt |
References |
Molecular Formula | C17H16N2O4S |
---|---|
Molecular Weight | 344.38500 |
Exact Mass | 344.08300 |
PSA | 98.58000 |
LogP | 3.94270 |